{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:54:43Z","timestamp":1773276883887,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.thromres.2014.05.041","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T11:16:44Z","timestamp":1402053404000},"page":"510-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications"],"prefix":"10.1016","volume":"134","author":[{"given":"Piotr","family":"Mazur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Soko\u0142owski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Hubalewska-Dydejczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"P\u0142aczkiewicz-Jankowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.05.041_bb0005","first-page":"225","article-title":"Embolic risk in atrial fibrillation that arises from hyperthyroidism: review of the medical literature","volume":"38","author":"Traube","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.thromres.2014.05.041_bb0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1076029610364521","article-title":"Hyperthyroidism and venous thrombosis: a casual or causal association? A systematic literature review","volume":"17","author":"Franchini","year":"2011","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.thromres.2014.05.041_bb0015","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1210\/jc.2007-0199","article-title":"Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review","volume":"92","author":"Squizzato","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.thromres.2014.05.041_bb0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1160\/TH11-10-0691","article-title":"The incidence of venous thromboembolism in patients with overt hyperthyroidism: a retrospective multicentre cohort study","volume":"107","author":"Kootte","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.041_bb0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/1076029609336856","article-title":"Venous thromboembolism in patients hospitalized with thyroid dysfunction","volume":"15","author":"Danescu","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.thromres.2014.05.041_bb0030","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2516.2007.01642.x","article-title":"Hypothyroidism and acquired von Willebrand's syndrome: a systematic review","volume":"14","author":"Manfredi","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2014.05.041_bb0035","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1210\/jcem.86.2.7221","article-title":"Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism","volume":"86","author":"Chadarevian","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.thromres.2014.05.041_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1507\/endocrj.K06-062","article-title":"Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement","volume":"54","author":"Akinci","year":"2007","journal-title":"Endocr J"},{"key":"10.1016\/j.thromres.2014.05.041_bb0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12020-009-9271-2","article-title":"Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism","volume":"36","author":"Erem","year":"2009","journal-title":"Endocrine"},{"key":"10.1016\/j.thromres.2014.05.041_bb0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12020-008-9116-4","article-title":"Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism","volume":"35","author":"Erem","year":"2009","journal-title":"Endocrine"},{"key":"10.1016\/j.thromres.2014.05.041_bb0055","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1160\/TH12-07-0496","article-title":"The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis","volume":"108","author":"Stuijver","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.041_bb0060","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1210\/jc.2006-2644","article-title":"Altered platelet plug formation in hyperthyroidism and hypothyroidism","volume":"92","author":"Homoncik","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.thromres.2014.05.041_bb0065","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1210\/en.2003-1372","article-title":"Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins","volume":"145","author":"Shih","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.thromres.2014.05.041_bb0070","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","article-title":"Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases","volume":"31","author":"Undas","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2014.05.041_bb0075","doi-asserted-by":"crossref","first-page":"310","DOI":"10.20452\/pamw.1083","article-title":"Acquired dysfibrinogenemia in atherosclerotic vascular disease","volume":"121","author":"Undas","year":"2011","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.thromres.2014.05.041_bb0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.atherosclerosis.2007.05.028","article-title":"Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress","volume":"196","author":"Undas","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2014.05.041_bb0085","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/01.ATV.0000241589.52950.4c","article-title":"Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis","volume":"26","author":"Collet","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2014.05.041_bb0090","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1161\/STROKEAHA.108.532812","article-title":"Altered fibrin clot structure\/function in patients with cryptogenic ischemic stroke","volume":"40","author":"Undas","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2014.05.041_bb0095","doi-asserted-by":"crossref","first-page":"608","DOI":"10.20452\/pamw.1535","article-title":"Altered fibrin clot properties in patients with premature peripheral artery disease","volume":"122","author":"Okraska-Bylica","year":"2012","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.thromres.2014.05.041_bb0100","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2009-05-222380","article-title":"Altered fibrin clot structure\/function in patients with idiopathic venous thromboembolism and in their relatives","volume":"114","author":"Undas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.05.041_bb0105","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.thromres.2010.04.007","article-title":"Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis","volume":"126","author":"Kwasny-Krochin","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.05.041_bb0110","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1210\/jc.2011-2894","article-title":"Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals","volume":"97","author":"Hooper","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.thromres.2014.05.041_bb0115","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/j.1538-7836.2012.04789.x","article-title":"Fibrin clot structure and fibrinolysis in hypothyroid individuals: the effects of normalising thyroid hormone levels","volume":"10","author":"Stuijver","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.041_bb0120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1160\/TH11-09-0662","article-title":"A history of early stent thrombosis is associated with prolonged clot lysis time","volume":"107","author":"Pankiw-Bembenek","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.041_bb0125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood-2010-02-267740","article-title":"Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1","volume":"116","author":"Meltzer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.05.041_bb0130","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1160\/TH10-03-0179","article-title":"A novel missense mutation in the FGB g. 3354T>A (p. Y41N), fibrinogen Caracas VIII","volume":"105","author":"Marchi","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.041_bb0135","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/1076029609350890","article-title":"Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism","volume":"16","author":"Ermantas","year":"2010","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.thromres.2014.05.041_bb0140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1160\/TH12-07-0525","article-title":"Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia","volume":"109","author":"Verkleij","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.041_bb0145","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2169\/internalmedicine.48.1758","article-title":"The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis","volume":"48","author":"Cetinkalp","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.thromres.2014.05.041_bb0150","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1172\/JCI29812","article-title":"Deiodinases: implications of the local control of thyroid hormone action","volume":"116","author":"Bianco","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2014.05.041_bb0155","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1210\/er.2008-0019","article-title":"Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling","volume":"29","author":"Gereben","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.thromres.2014.05.041_bb0160","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jacc.2012.03.047","article-title":"Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults","volume":"60","author":"Tseng","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.05.041_bb0165","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1089\/thy.2011.0222","article-title":"Relative levels of the inflammatory cytokine TNFalpha and the soluble CD40 ligand profile in serum correlate with the thyrotoxic activity of Graves' disease","volume":"22","author":"Yamamoto","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.thromres.2014.05.041_bb0170","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1507\/endocrj.43.709","article-title":"Plasma selectin levels in patients with Graves' disease","volume":"43","author":"Hara","year":"1996","journal-title":"Endocr J"},{"key":"10.1016\/j.thromres.2014.05.041_bb0175","doi-asserted-by":"crossref","first-page":"327","DOI":"10.14310\/horm.2002.1111029","article-title":"The alteration of serum soluble CD40 ligand levels in overt and subclinical hypothyroidism","volume":"6","author":"Akinci","year":"2007","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.thromres.2014.05.041_bb0180","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/09537104.2010.508130","article-title":"Mean platelet volume in patients with subclinical hypothyroidism","volume":"22","author":"Yilmaz","year":"2011","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2014.05.041_bb0185","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1538-7836.2006.01903.x","article-title":"Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis","volume":"4","author":"Undas","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.041_bb0190","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00125-005-1742-2","article-title":"The influence of type 2 diabetes on fibrin structure and function","volume":"48","author":"Dunn","year":"2005","journal-title":"Diabetologia"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814003223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814003223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T07:31:24Z","timestamp":1746257484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814003223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0049384814003223"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.05.041","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}